Apogee Therapeutics reported positive Phase 2 trial results for its anti-IL-13 antibody APG777 in atopic dermatitis, achieving a 71% reduction in eczema severity after 16 weeks. The treatment met its primary endpoints and demonstrated clinical responses comparable or superior to current biologics like Dupixent. APG777’s potential for less frequent dosing (quarterly or biannually) could offer improved convenience. The drug showed a favorable safety profile, and expanded trials, including Phase 3, are planned to further explore its therapeutic potential.